Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with ...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, …